文献速递骨软组织肉瘤与黑色素瘤

晚期转移性黑色素瘤通过多种进化途径产生

Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.
PubMed 文献 · Cancer Discov · 2023-01-01

研究利用PEACE研究尸检程序,对14例接受ICI治疗的黑色素瘤患者进行多组学分析,包括222例外显子组测序、493例面板测序、161例RNA测序和22例单细胞全基因组测序样本,揭示了全基因组加倍、杂合性缺失、KIT染色体外DNA、MYC扩增及脑转移早期分子进化等多样进化途径。

要点

  • 全基因组加倍和杂合性缺失频繁发生,常涉及抗原提呈机制。
  • KIT染色体外DNA可能导致KIT驱动黑色素瘤对KIT抑制剂无响应。
  • 病变水平MYC扩增在ICI无应答者中富集;脑转移早期分子进化分歧但晚期出现。

核心结论

  • 研究阐明了晚期黑色素瘤通过突变、广泛拷贝数改变或染色体外DNA等多种机制逃逸治疗和免疫系统的进化图景。

研究设计与样本

  • 研究为PEACE研究尸检程序的一部分,纳入14例接受ICI治疗的患者,采集222例外显子组测序、493例面板测序、161例RNA测序和22例单细胞全基因组测序样本。

主要发现

  • 频繁观察到全基因组加倍和广泛杂合性缺失,常涉及抗原提呈机制。
  • KIT染色体外DNA可能 contributed 至KIT驱动黑色素瘤对KIT抑制剂无响应。
  • 病变水平MYC扩增在ICI无应答者中富集。
  • 单细胞测序显示一名患者转移灶来自不同倍性克隆的多克隆播种。
  • 脑转移在分子进化早期分歧但疾病晚期出现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Understanding the evolutionary pathways to metastasis and resistance to immune-checkpoint inhibitors (ICI) in melanoma is critical for improving outcomes. Here, we present the most comprehensive intrapatient metastatic melanoma dataset assembled to date as part of the Posthumous Evaluation of Advanced Cancer Environment (PEACE) research autopsy program, including 222 exome sequencing, 493 panel-sequenced, 161 RNA sequencing, and 22 single-cell whole-genome sequencing samples from 14 ICI-treated patients. We observed frequent whole-genome doubling and widespread loss of heterozygosity, often involving antigen-presentation machinery. We found KIT extrachromosomal DNA may have contributed to the lack of response to KIT inhibitors of a KIT-driven melanoma. At the lesion-level, MYC amplifications were enriched in ICI nonresponders. Single-cell sequencing revealed polyclonal seeding of metastases originating from clones with different ploidy in one patient. Finally, we observed that brain metastases that diverged early in molecular evolution emerge late in disease. Overall, our study illustrates the diverse evolutionary landscape of advanced melanoma. SIGNIFICANCE: Despite treatment advances, melanoma remains a deadly disease at stage IV. Through research autopsy and dense sampling of metastases combined with extensive multiomic profiling, our study elucidates the many mechanisms that melanomas use to evade treatment and the immune system, whether through mutations, widespread copy-number alterations, or extrachromosomal DNA. See related commentary by Shain, p. 1294. This article is highlighted in the In This Issue feature, p. 1275.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Spain L, Coulton A, Lobon I, et al. Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways. Cancer Discov. 2023. PMID: 36977461. doi:10.1158/2159-8290.CD-22-1427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。